GBG HOME

ESMO Breast Cancer Meeting

22.04.2022

GBG research at ESMO Breast Cancer Meeting 2022 May 3rd to 5th in Berlin.

Visit us at booth No 20 and visit our presentations.

SASCIA - Oral presentation #58O
Date: Wed, 04.05.2022. Lecture time: 16:45
Session: Proffered Paper session 2
Chairs: G. Curigliano S. Delaloge S. Kim
Speakers: F. Marmé
Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment.
F. Marmé, C. Hanusch, J. Furlanetto, et al.

PenelopeB - Mini oral #60MO
Date: Tue, 03.05.2022. Lecture time: 16:22 - 16:29
Session: Mini Oral session 1
Chairs: L. Del Mastro P. Poortmans
Speakers: J. Furlanetto
Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): explorative analysis in Penelope-B
J. Furlanetto, F. Marmé, C. Thode, et al.

BMBC - Poster #170P
Date: Wed, 04.05.2022. Lecture Time: 12:15 - 13:00
Speakers: K. Riecke
Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC Registry
K. Riecke, E. Laakmann, T. Neunhöffer, et al.

GeparX - Poster #94P
Date: Wed, 04.05.2022. Lecture Time: 12:15 - 13:00
Speakers: M. Reinisch
Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)
M. Reinisch, J.-U. Blohmer, T. Link, et al.

GeparQuattro, GeparQuinto and GeparSixto - Poster #24P
Date: Wed, 04.05.2022
Lecture Time: 12:15 - 13:00
Speakers: B. Sinn
Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome
B. Sinn, M. Untch, T. Karn, et al.

ESMO Breast Cancer 3.-5. May 2022

News

  • 18.11.2022 Desiree: dose escalation of everolimus published

    Desiree: dose escalation of everolimus published

    We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.

    Mehr ...
  • 10.11.2022 Deutscher Krebskongress

    Deutscher Krebskongress

    Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.

    Mehr ...
  • 08.11.2022 GBG research at SABCS 2022

    GBG research at SABCS 2022

    We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10

    Mehr ...
  • 14.10.2022 Location of Subcutaneous Trastuzumab Injection

    Location of Subcutaneous Trastuzumab Injection

    Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study

    Mehr ...

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd